Glipizide

This classification denotes an anti-diabetic agent with the molecular formula C21H27N5O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) X7WDT95N5C, chemically known as urea, 1-cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)- but more generally known as glipizide, which bears US NIH Compound Identifier 3478. European Medicines Agency schedules Glipizide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07927MIG. The term GLIPIZIDE is an International Non-Proprietary Name WHO schedules glipizide in its Anatomical Therapeutic Chemical (ATC) Classification. GLIPIZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule glipizide under HS 29350090 and SITC 51580. As of Q4 2014, GLIPIZIDE remains US FDA's Preferred Term for this commodity. Glipizide bears US NLM identifiers UMLS ID C0017642 and NCI Concept Code C29074. SMILES: S(=O)(=O)(NC(=O)NC1CCCCC1)C1CCC(CCNC(=O)C2NCC(NC2)C)CC1.